2 results
Approved WMOPending
This Phase 2 study for JNJ-63733657 will assess the possible slowing of cognitive decline seen inprodromal AD and mild AD dementia (Early AD). In addition, effects of JNJ-63733657 on theaccumulation of tau, as measured by tau positron emission…
Approved WMORecruiting
Primary objectivesPart 1 Dose Escalation (with or without LDSC-IL2)• To investigate the safety and tolerability of LAVA-1207 in patients with therapy refractory mCRPC.• To determine the RP2D of LAVA-1207 in patients with therapy refractory mCRPC.…